RxDoctor Payments Data

Dena Jackson, MD

Internal Medicine · Brookhaven, MSNPI 1477663318

Payments from drug & device makers

$6,881in general payments, 2019–2025

Across 472 payments — averaging $14.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$651
  • Novo Nordisk$630
  • AstraZeneca$628
  • Pfizer$483
  • GSK$468
  • Lilly USA, LLC$377
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$6,869100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,881 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$50,217
Medicare patients
302
Services billed
803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide191$231,189
EliquisApixaban216$203,391
JardianceEmpagliflozin166$167,645
MounjaroTirzepatide95$113,183
FarxigaDapagliflozin Propanediol91$70,961
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$67,005
TrulicityDulaglutide57$53,655
XareltoRivaroxaban43$37,215
LinzessLinaclotide28$32,354
Tresiba Flextouch U-100Insulin Degludec42$22,886
MyrbetriqMirabegron38$22,630
Soliqua 100-33Insulin Glargine/Lixisenatide15$17,912
Repatha SureclickEvolocumab19$14,480
Breo ElliptaFluticasone/Vilanterol26$11,777
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$11,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$630$231,189191 claims
PfizerEliquis$483$203,391216 claims
Boehringer IngelheimJardiance$116$167,645166 claims
Lilly USA, LLCMounjaro, Trulicity$377$166,839152 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$628$89,236137 claims
GSKTrelegy Ellipta, Breo Ellipta$468$78,782107 claims
Johnson & JohnsonXarelto$166$37,21543 claims
AbbVieLinzess, Synthroid$371$36,22487 claims
Astellas Pharma US IncMyrbetriq$32$22,63038 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$298$17,91215 claims
BayerKerendia$328$6,94511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Brookhaven

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →